4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 85.21M | 120.00K | 33.00K | 23.00K | 37.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.21M | 120.00K | 33.00K | 23.00K | 37.00K |
| Cost of Revenue | 193.40M | 178.98M | 170.22M | 154.13M | 141.30M |
| Gross Profit | -108.19M | -178.86M | -170.19M | -154.11M | -141.26M |
| SG&A Expenses | 49.06M | 49.32M | 50.14M | 49.22M | 46.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.46M | 228.30M | 220.36M | 203.35M | 187.88M |
| Operating Income | -157.25M | -228.18M | -220.33M | -203.33M | -187.84M |
| Income Before Tax | -140.11M | -209.18M | -196.14M | -176.44M | -160.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.11 | -209.18 | -196.14 | -176.44 | -160.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.11M | -209.18M | -196.14M | -176.44M | -160.87M |
| EBIT | -157.25M | -228.18M | -220.33M | -203.33M | -187.84M |
| EBITDA | -152.55M | -223.61M | -215.82M | -198.80M | -183.19M |
| EPS Basic | -2.55 | -3.74 | -3.52 | -3.17 | -2.97 |
| Normalized Basic EPS | -1.57 | -2.32 | -2.20 | -1.98 | -1.86 |
| EPS Diluted | -2.55 | -3.74 | -3.52 | -3.17 | -2.97 |
| Normalized Diluted EPS | -1.57 | -2.32 | -2.20 | -1.98 | -1.86 |
| Average Basic Shares Outstanding | 231.72M | 223.44M | 222.87M | 222.22M | 215.75M |
| Average Diluted Shares Outstanding | 231.72M | 223.44M | 222.87M | 222.22M | 215.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |